Long-acting thyroid stimulator (LATS) and long acting thyroid stimulator protector (LATS-P) in untreated...

The prevalence of serum LATS and LATS-P in untreated Graves' disease has been studied in eighty-three patients with thyroid overactivity; twelve (14%) were found to have significant levels of LATs and LATS-P whilst fifty-nine (72%) had significant levels of LATS-P alone. Twelve (14%) had neither activity. There was a very wide range in both activities. LATS was invariably found in association with a significantly greater concentration of LATS-P. There was no correlation between LATS-P and thyroid mass, as estimated from scintiscanning, thyroidal radioiodine uptake at 4 and 48 h, total serum T4 and total serum T3. Neither LATS nor LATS-P were detected in eleven patients with toxic multinodular goitre nor four with solitary toxic adenoma.